Navigation Links
Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
Date:12/13/2011

NEW YORK, Dec. 13, 2011 /PRNewswire/ -- Synergy Pharmaceuticals, Inc. (Nasdaq: SGYPD, SGYPU), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that it has filed a lawsuit in New York State Supreme Court against Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie. 

The lawsuit alleges that after European patent 1,379,224 was granted to Synergy but prior to issuance, Ironwood and Dr. Currie opposed the patent before the European Patent Office and presented to the European Patent Office and the United States Patent and Trademark Office, data and arguments that were false, contradictory, inaccurate and misleading.  In its complaint, Synergy accuses Ironwood and Dr. Currie of, among other things, unfair competition, fraud and unjust enrichment and seeks $500 million in actual and punitive damages.

About Synergy Pharmaceuticals, Inc.

Synergy is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and diseases. Synergy's proprietary drug candidate plecanatide is a synthetic analog of the human gastrointestinal hormone uroguanylin, and functions by activating the guanylate cyclase C receptor on epithelial cells of the GI tract. Synergy completed a Phase I study of plecanatide in healthy volunteers and a Phase IIa clinical trial in patients to treat chronic idiopathic constipation (CIC) patients. In October 2011, Synergy initiated dosing of patients in a major Phase II/III clinical trial of plecanatide in CIC patients. Plecanatide is also being developed to treat constipation-predominant irritable bowel syndrome, with the first trial in IBS-C patients planned for 2012. Synergy's second GC-C agonist SP-333 is currently in pre-clinical development to treat inflammatory bowel diseases. More information is available at http://www.synergypharma.com.  


'/>"/>
SOURCE Synergy Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Synergy Business Solutions Acquires the Microsoft Dynamics SL Practice of Congruent Software, Inc.
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
4. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
5. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
6. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
7. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
8. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
9. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
10. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
11. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/10/2020)... ... January 09, 2020 , ... A new report from ... the vendor qualification process, a critical element of clinical trial set up and ... the vendor qualification process creates delays in initiation in 7% of clinical trials ...
(Date:1/10/2020)... ... January 09, 2020 , ... GenScript Biotech Corp., one of ... Forum on Jan. 14 in San Francisco, coinciding with the JP Morgan Healthcare ... Booming China Market," will feature gene and cell therapy leaders in industry, academia ...
(Date:1/8/2020)... NORWALK, Conn. (PRWEB) , ... January 08, 2020 ... ... practice whose exceptional quality and care helps couples and individuals grow their family, ... the prestigious Top Doc award by Castle Connolly. Since 1991, the renowned publishing ...
(Date:1/7/2020)... N.J. (PRWEB) , ... January 07, 2020 , ... Vuja ... prevent cancer progression and recurrence, today announced the appointments of Chand Khanna, DVM, PhD, ... Co-founder and CEO of Vuja De said, “We are delighted to welcome Chand and ...
Breaking Biology Technology:
(Date:2/13/2020)... ... February 13, 2020 , ... Pharmica Consulting ... clinical operations executives and focusing on all facets of clinical trial planning and ... patient engagement, and more. , “We have attended the SCOPE Summit every ...
(Date:2/11/2020)... ... 11, 2020 , ... Modality Solutions, a leading ... 9001:2015 registration by certification body Intertek. Modality Solutions’ Quality Manager, Hannah Anderson, spearheaded ... existing Standard Operating Procedures (SOPs) and created ten new SOPs. Anderson trained staff ...
(Date:2/11/2020)... BALTIMORE (PRWEB) , ... February 11, 2020 , ... ... has moved into The LaunchPort™ medical device accelerator in Port Covington, Baltimore. The ... the issues that must be addressed to manage increased demand for home dialysis ...
Breaking Biology News(10 mins):